Aleah Caulin

Aleah Caulin's work experience includes several roles in the biotechnology and healthcare industries. Aleah started their career at the DOE Joint Genome Institute in 2012, where they worked as a Researcher on a project integrating single cell genomics and metagenomics. From 2008 to 2013, they pursued a doctoral degree at the University of Pennsylvania, specializing in genomics and computational biology. During this time, they also served as a DOE Computational Science Graduate Fellow, conducting research on the evolution of cancer suppression in large organisms.

After completing their studies, Aleah joined Driver, a company focused on connecting cancer patients to life-prolonging therapies. Aleah held various roles at Driver, including Head of Partner Product, Head of Product, Clinical Computational Biology Lead, and Bioinformatics Analyst, between 2014 and 2018.

In 2018, Aleah joined Anchor Health as part of the Advisory Board. Finally, in 2019, they joined Peel Therapeutics as the Director of Preclinical Studies. In July 2021, they were promoted to the role of VP, Nonclinical, where they continue to contribute to the company's mission of developing treatments for life-threatening conditions.

Aleah Caulin completed a Bachelor of Science degree in Biology & Computer Science from Boston College, where they studied from 2004 to 2008. Following their undergraduate studies, they pursued a Doctor of Philosophy (Ph.D.) degree at the University of Pennsylvania, specializing in Genomics and Computational Biology. Aleah attended the University of Pennsylvania from 2008 to 2013 and successfully obtained their Ph.D.